Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Divestments (2021 - 2025)

BridgeBio Pharma (BBIO) has disclosed Divestments for 3 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • Quarterly Divestments changed N/A to $2.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 91.04% year-over-year, with the annual reading at $2.3 million for FY2025, 91.04% down from the prior year.
  • Divestments hit $2.3 million in Q3 2025 for BridgeBio Pharma, down from $25.7 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $29.4 million in Q4 2021 to a low of $2.3 million in Q3 2025.
  • Historically, Divestments has averaged $19.1 million across 3 years, with a median of $25.7 million in 2024.